EU/3/12/959

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

On 9 February 2012, orphan designation (EU/3/12/959) was granted by the European Commission to Endocyte Europe B.V., the Netherlands, for vincaleukoblastin-23-oic acid, O4-deacetyl-, 2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine for the treatment of ovarian cancer.

 

Key facts

Active substance
Vincaleukoblastin-23-oic acid, O4-deacetyl-, 2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine
Medicine name
Vynfinit
Disease / condition
Treatment of ovarian cancer
Date of first decision
09/02/2012
Outcome
Withdrawn
EU designation number
EU/3/12/959

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

Sponsor's contact details

Endocyte Europe B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
The Netherlands
Telephone: +31 20 521 4777
Telefax: +31 20 521 4821
E-mail: info@endocyte.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating